Skip to content
Open access · CC-BY via OpenAlex

Progeria, rapamycin and normal aging: recent breakthrough

Mikhail V. Blagosklonny

Aging · 2011 · ▲ 50 citations

Abstract

A recent discovery that mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) suppresses a pro-senescent phenotype in progeric cells not only suggests a non-toxic therapy for progeria but also implies its similarity with normal aging. For one, rapamycin is also known to suppress aging of regular human cells. Here I discuss four potential scenarios, comparing progeria with both normal and accelerated aging. This reveals further indications of rapamycin both for accelerated aging in obese and for progeria.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.18632/aging.100352
Canonical
link ↗
Fetched
2026-06-13 MST

Cite this

APA
Blagosklonny, M.V. (2011). Progeria, rapamycin and normal aging: recent breakthrough. <em>Aging</em>. https://doi.org/10.18632/aging.100352
Vancouver
Blagosklonny MV. Progeria, rapamycin and normal aging: recent breakthrough. Aging. 2011. doi:10.18632/aging.100352.
BibTeX
@article{mikhail2011Proger, title = {Progeria, rapamycin and normal aging: recent breakthrough}, author = {Mikhail V. Blagosklonny}, journal = {Aging}, year = {2011}, doi = {10.18632/aging.100352}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings